Acquired in December, Vocan has now received and assembled the required equipment to go forward with their plans to produce biosynthesized psilocybin. The company considers this a critical milestone in their development plan because of the cost and long lead times associated with the acquisition. Now Vocan is able to improve their present lab work and are actually ahead of schedule on its plans for beginning the rocombinant production of psilocybin.
“Vocan’s recombinant production of psilocybin is a significant improvement over the current methods of psilocybin production. Reducing both the cost and time needed to produce and purify psilocybin to only a few days, compared to much longer and more expensive methods for whole mushroom extraction. Having the equipment purchased and assembled positions Vocan to execute on its objectives in the short term,” said Joel Shacker, Core One’s CEO.
Core One is a biotech research and development company involved in life sciences and more specifically in the developing psychedelic space. They’re developing novel delivery systems to be used in psychedelic assisted psychotherapy. They have a patent pending thin film oral strip, which dissolves inside the mouth and delivers the desired chemical directly to the bloodstream. The company intends on furthering its technology intellectual property by focusing on psychedelic delivery, with their first target being psilocybin.
Vocan’s platform can duplicate naturally occurring compounds in a lab using a gene mimicry process and simple chemical modifications. The process involves engineering bacteria using optimized biosynthetic genes from the Psilocybe cubensis mushrooms, which enables the bacteria to act as a biological factory in order to artificially develop psilocybin.
Core One Labs seems to have taken the adage new year new you to heart. They recently only came back online after shedding their old skin (they were once Lifestyle Delivery Systems) and bouncing back with a new gameplan, new blood and new vigor. When they returned midway through November they were barely a $0.30 play and a shaky one at that as they had yet to prove themselves to both new and long-time investors. But now it would seem that COOL’s near triple has finally rewarded those who wait and keep the faith.
Full disclosure: Core One Labs is an equity.guru marketing client.